NBC Securities’s Ocular Therapeutix OCUL Stock Holding History

NBC Securities’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-100	Closed	-$847	–	2496
2026 Q1	$847	Buy	+100	New	+$953	﹤0.01%	2438

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NBC Securities's OCUL Position: Q2 2026 in Review

NBC Securities sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 100 shares — an estimated $847 sold.

NBC Securities first reported a position in OCUL in Q1 2026 and held it in 1 quarter. The position peaked at $847 in Q1 2026. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

NBC Securities reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
NBC Securities sold 100 Ocular Therapeutix shares in Q2 2026, an estimated $847.
NBC Securities first reported a position in Ocular Therapeutix in Q1 2026 and held it in 1 quarter.
NBC Securities's Ocular Therapeutix position peaked at $847 in Q1 2026.
261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on NBC Securities's 13F filing for Q2 2026, filed 21 Jul 2026.